July 26, 2026
SOHO Insider Hem/Onc Library Meetings / Conferences EHA 2026

EHA 2026

News from the EHA 2026 Congress held in Stockholm, Sweden.

Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

What is the patient quality of life on the SUCCESOR-2 trial?

Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

How to sequence mezigdomide-based therapy in myeloma?

Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?

SUCCESSOR 2
Focus on CELMoDs EHA 2026 Meetings / Conferences Multiple Myeloma Roundtable Discussions Video Interviews

What is the phase 3 SUCCESSOR-2 trial?

EHA 2026 Cellular Therapy Leukemia Acute Lymphoblastic Leukemia Meetings / Conferences

Nanobody-based anti-CD5 CAR T agent improves efficacy in relapsed or refractory T-cell ALL

EHA 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis Video Interviews

Early-phase trial data of INCA033989 shows durable responses in MF

keyboard
EHA 2026 Multiple Myeloma

MajesTEC-3 trial post-hoc analysis: Teclistamab regimen boosts survival across risk in myeloma

EHA 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis

Post-transplant molecular monitoring could prompt preemptive intervention in patients with myelofibrosis

Young scientists conducting research investigations in a medical laboratory, a researcher in the foreground is using a microscope
EHA 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis

Novel germline JAK2 mutation linked to progression to MF in MPN

EHA 2026 Meetings / Conferences Myeloproliferative Neoplasms Primary Myelofibrosis

ERNEST-3 analysis characterizes prevalence of cytopenic MF and treatment trends